id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-317761-tkqmu1va	Shukla, Ashutosh M	Chloroquine and hydroxychloroquine in the context of COVID-19	2020-04-28		.txt	text/plain	4111	191	42	This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment. 1 These agents have also shown a promising role in viral infections, and with the recent declaration on March 12th, 2020, by the World Health Organization that coronavirus disease (COVID) of 2019 (COVID-19) is a pandemic, these compounds have rapidly gained worldwide attention for their ability to control the causative virus, severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2). 1 These include inhibition of ligand-based toll-like receptor stimulation, inhibition of nuclear factor kappalight-chain-enhancer of activated B cells (NFkB) pathways in macrophages with resultant reduction in the generation of pro-inflammatory cytokines, reduced processing of the endogenous and exogenous ligands through lysosomes and endosomes with resultant reduction in the availability of processed antigens for presentation to the major ISSN: 1740-4398 REVIEW -Chloroquine, hydroxychloroquine, and COVID-19 drugsincontext.com histocompatibility complex-T cell receptor interactions, and downstream activation of cellular immunity.	./cache/cord-317761-tkqmu1va.txt	./txt/cord-317761-tkqmu1va.txt